vs
ESCO TECHNOLOGIES INC（ESE）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ESCO TECHNOLOGIES INC的季度营收约是Orthofix Medical Inc.的1.3倍（$289.7M vs $219.9M），ESCO TECHNOLOGIES INC净利率更高（9.9% vs -1.0%，领先10.9%），ESCO TECHNOLOGIES INC同比增速更快（17.3% vs 2.0%），ESCO TECHNOLOGIES INC自由现金流更多（$63.0M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 7.8%）
ESCO是来自新加坡的品牌，专注于实验室领域相关产品及服务的研发、生产与销售，可为各类科研、检测及工业实验室提供适配的产品解决方案与配套支持，产品广泛应用于生命科学、医疗健康、工业检测等多个领域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ESE vs OFIX — 直观对比
营收规模更大
ESE
是对方的1.3倍
$219.9M
营收增速更快
ESE
高出15.3%
2.0%
净利率更高
ESE
高出10.9%
-1.0%
自由现金流更多
ESE
多$46.1M
$16.8M
两年增速更快
OFIX
近两年复合增速
7.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $289.7M | $219.9M |
| 净利润 | $28.7M | $-2.2M |
| 毛利率 | 41.4% | 71.1% |
| 营业利润率 | 13.2% | 0.2% |
| 净利率 | 9.9% | -1.0% |
| 营收同比 | 17.3% | 2.0% |
| 净利润同比 | 22.2% | 92.4% |
| 每股收益（稀释后） | $1.11 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESEOFIX
| Q4 25 | $289.7M | $219.9M | ||
| Q3 25 | $286.5M | $205.6M | ||
| Q2 25 | $296.3M | $203.1M | ||
| Q1 25 | $265.5M | $193.6M | ||
| Q4 24 | $247.0M | $215.7M | ||
| Q3 24 | $298.5M | $196.6M | ||
| Q2 24 | $260.8M | $198.6M | ||
| Q1 24 | $249.1M | $188.6M |
净利润ESEOFIX
| Q4 25 | $28.7M | $-2.2M | ||
| Q3 25 | $218.7M | $-22.8M | ||
| Q2 25 | $26.1M | $-14.1M | ||
| Q1 25 | $31.0M | $-53.1M | ||
| Q4 24 | $23.5M | $-29.1M | ||
| Q3 24 | $34.3M | $-27.4M | ||
| Q2 24 | $29.2M | $-33.4M | ||
| Q1 24 | $23.2M | $-36.0M |
毛利率ESEOFIX
| Q4 25 | 41.4% | 71.1% | ||
| Q3 25 | 45.9% | 72.2% | ||
| Q2 25 | 41.2% | 68.7% | ||
| Q1 25 | 41.1% | 62.8% | ||
| Q4 24 | 39.8% | 69.0% | ||
| Q3 24 | 40.1% | 68.7% | ||
| Q2 24 | 39.6% | 67.8% | ||
| Q1 24 | 38.8% | 67.5% |
营业利润率ESEOFIX
| Q4 25 | 13.2% | 0.2% | ||
| Q3 25 | 17.2% | -8.3% | ||
| Q2 25 | 11.2% | -7.9% | ||
| Q1 25 | 15.3% | -25.2% | ||
| Q4 24 | 11.4% | -5.3% | ||
| Q3 24 | 14.8% | -9.6% | ||
| Q2 24 | 14.3% | -12.5% | ||
| Q1 24 | 11.7% | -15.6% |
净利率ESEOFIX
| Q4 25 | 9.9% | -1.0% | ||
| Q3 25 | 76.3% | -11.1% | ||
| Q2 25 | 8.8% | -6.9% | ||
| Q1 25 | 11.7% | -27.4% | ||
| Q4 24 | 9.5% | -13.5% | ||
| Q3 24 | 11.5% | -13.9% | ||
| Q2 24 | 11.2% | -16.8% | ||
| Q1 24 | 9.3% | -19.1% |
每股收益（稀释后）ESEOFIX
| Q4 25 | $1.11 | $-0.05 | ||
| Q3 25 | $8.43 | $-0.57 | ||
| Q2 25 | $1.01 | $-0.36 | ||
| Q1 25 | $1.20 | $-1.35 | ||
| Q4 24 | $0.91 | $-0.76 | ||
| Q3 24 | $1.32 | $-0.71 | ||
| Q2 24 | $1.13 | $-0.88 | ||
| Q1 24 | $0.90 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $103.8M | $82.0M |
| 总债务越低越好 | $145.5M | — |
| 股东权益账面价值 | $1.6B | $450.0M |
| 总资产 | $2.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
现金及短期投资ESEOFIX
| Q4 25 | $103.8M | $82.0M | ||
| Q3 25 | $101.3M | $62.9M | ||
| Q2 25 | $78.7M | $65.6M | ||
| Q1 25 | $57.4M | $58.0M | ||
| Q4 24 | $71.3M | $83.2M | ||
| Q3 24 | $66.0M | $30.1M | ||
| Q2 24 | $63.0M | $26.4M | ||
| Q1 24 | $59.4M | $27.0M |
总债务ESEOFIX
| Q4 25 | $145.5M | — | ||
| Q3 25 | $186.0M | $157.2M | ||
| Q2 25 | $525.0M | $157.0M | ||
| Q1 25 | $88.0M | $156.9M | ||
| Q4 24 | $112.0M | $157.0M | ||
| Q3 24 | $122.0M | $118.5M | ||
| Q2 24 | $173.0M | $118.0M | ||
| Q1 24 | $191.0M | $118.2M |
股东权益ESEOFIX
| Q4 25 | $1.6B | $450.0M | ||
| Q3 25 | $1.5B | $442.5M | ||
| Q2 25 | $1.3B | $458.3M | ||
| Q1 25 | $1.3B | $458.3M | ||
| Q4 24 | $1.2B | $503.1M | ||
| Q3 24 | $1.2B | $525.9M | ||
| Q2 24 | $1.2B | $546.0M | ||
| Q1 24 | $1.2B | $570.3M |
总资产ESEOFIX
| Q4 25 | $2.4B | $850.6M | ||
| Q3 25 | $2.4B | $832.6M | ||
| Q2 25 | $2.5B | $837.2M | ||
| Q1 25 | $1.8B | $823.1M | ||
| Q4 24 | $1.8B | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $1.8B | $882.0M | ||
| Q1 24 | $1.8B | $906.0M |
负债/权益比ESEOFIX
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.12× | 0.36× | ||
| Q2 25 | 0.40× | 0.34× | ||
| Q1 25 | 0.07× | 0.34× | ||
| Q4 24 | 0.09× | 0.31× | ||
| Q3 24 | 0.10× | 0.23× | ||
| Q2 24 | 0.14× | 0.22× | ||
| Q1 24 | 0.16× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $68.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $63.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 21.7% | 7.6% |
| 资本支出强度资本支出/营收 | 2.0% | 4.9% |
| 现金转化率经营现金流/净利润 | 2.40× | — |
| 过去12个月自由现金流最近4个季度 | $239.6M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ESEOFIX
| Q4 25 | $68.9M | $27.7M | ||
| Q3 25 | $109.9M | $12.4M | ||
| Q2 25 | $73.7M | $11.6M | ||
| Q1 25 | $24.1M | $-18.4M | ||
| Q4 24 | $34.2M | $23.7M | ||
| Q3 24 | $72.1M | $11.7M | ||
| Q2 24 | $36.2M | $9.0M | ||
| Q1 24 | $10.5M | $-18.6M |
自由现金流ESEOFIX
| Q4 25 | $63.0M | $16.8M | ||
| Q3 25 | $97.8M | $2.5M | ||
| Q2 25 | $64.9M | $4.5M | ||
| Q1 25 | $14.0M | $-25.1M | ||
| Q4 24 | $29.0M | $15.2M | ||
| Q3 24 | $60.9M | $6.3M | ||
| Q2 24 | $27.6M | $-360.0K | ||
| Q1 24 | $2.0M | $-29.1M |
自由现金流率ESEOFIX
| Q4 25 | 21.7% | 7.6% | ||
| Q3 25 | 34.1% | 1.2% | ||
| Q2 25 | 21.9% | 2.2% | ||
| Q1 25 | 5.3% | -13.0% | ||
| Q4 24 | 11.7% | 7.0% | ||
| Q3 24 | 20.4% | 3.2% | ||
| Q2 24 | 10.6% | -0.2% | ||
| Q1 24 | 0.8% | -15.4% |
资本支出强度ESEOFIX
| Q4 25 | 2.0% | 4.9% | ||
| Q3 25 | 4.2% | 4.8% | ||
| Q2 25 | 3.0% | 3.5% | ||
| Q1 25 | 3.8% | 3.5% | ||
| Q4 24 | 2.1% | 4.0% | ||
| Q3 24 | 3.8% | 2.7% | ||
| Q2 24 | 3.3% | 4.7% | ||
| Q1 24 | 3.4% | 5.6% |
现金转化率ESEOFIX
| Q4 25 | 2.40× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
